• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Mackenzie's Mission HomepageMackenzie's Mission

DONATE Mackenzies Mission Donate
  • Mission
  • About
    • The Story
    • Board
  • Resources
    • Resource List
    • What Is Amyloidosis
  • Speakers Bureau
    • About ASB
    • ASB Operating Committee
  • Fundraisers
  • Blog
  • Contact

amyloidosis treatment

CRISPR/Cas9 – ATTR Clinical Trial Update

November 17, 2022

Per the National Institute of Health, “One of the most promising areas of research in recent years has been gene editing, including CRISPR/Cas9, for fixing misspellings in genes to treat or even cure many conditions.” In this piece we provide a clinical trial update for transthyretin (TTR) amyloidosis using this technology.

Filed Under: Featured News, What Is Amyloidosis Tagged With: #crispr, Amyloid cardiomyopathy, amyloidosis, amyloidosis diagnosis, amyloidosis research, amyloidosis treatment, ATTR amyloidosis, ATTRwt, hATTR

FDA Approved AMVUTTRA for hATTR

June 14, 2022

Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Filed Under: Featured News, What Is Amyloidosis Tagged With: amyloidosis, amyloidosis treatment, ATTR amyloidosis, attrv, FDA Approved, hATTR, Hereditary Amyloidosis

AL Amyloidosis vs Multiple Myeloma

October 28, 2021

In reality, while there are ample similarities where some view AL amyloidosis and multiple myeloma as “cousins,” there are important differences.

Filed Under: Featured News, What Is Amyloidosis Tagged With: AL amyloidosis, amyloidosis, amyloidosis treatment, blood diseases, light chain amyloidosis, multiple myeloma

CRISPR/Cas9 – Editing the Code of Life

March 20, 2021

The scientific world is abuzz … a Nobel Prize-winning technology called CRISPR/Cas9 can now edit our DNA. This programmable gene-editing technology, which is efficient, precise, and scalable, has inspired a gold rush of countless applications in medicine, agriculture and basic science.  In this blog we invite you to read more about this ground-breaking advance and how, with one course of treatment, it could potentially cure hereditary transthyretin (hATTR / ATTRv) amyloidosis.

Filed Under: Featured News, What Is Amyloidosis Tagged With: #clinicaltrials, #crispr, #crispr/cas9, amyloidosis, amyloidosis clinical trials, amyloidosis news, amyloidosis treatment, ATTR amyloidosis, attrv, hATTR, Hereditary Amyloidosis, hereditaryamyloidosis

1st FDA-Approved Drug for AL Amyloidosis

January 16, 2021

After decades of relying on treatments approved for other diseases, on January 15, 2021 the FDA approved the first drug for AL Amyloidosis. Truly a game-changing, monumental advancement in the treatment of this disease.

Filed Under: Featured News, What Is Amyloidosis Tagged With: #Andromeda, AL amyloidosis, amyloidosis, amyloidosis clinical trials, amyloidosis news, amyloidosis treatment

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 6
  • Go to Next Page »

Primary Sidebar

Recent News

  • Worldwide Hotspots of Hereditary ATTR Amyloidosis (ATTRv)
  • 2022: Mackenzie’s Mission – Our Report Card
  • CRISPR/Cas9 – ATTR Clinical Trial Update
  • Heart Failure & Amyloidosis
  • Over 10,000 medical students and residents!!

Be A Part Of Our Mission!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

  • Mission
  • About
  • Resources
  • Speakers Bureau
  • Fundraisers
  • Blog
  • Contact

Registered 501(c)(3) · Contact · Copyright © 2023 · Mackenzies Mission - All Rights Reserved